Partial
Partially Aligned
Patient Risk:
Low
Summary
Most claims are about biosimilar development/market/price and biologic structural comparability, which are not addressed in the provided COSENTYX (secukinumab) prescribing information excerpts. The only label-relevant, on-label type claim—Cosentyx treats multiple conditions—is partially aligned depending on the label scope, but other claims are largely unsupported by the supplied label excerpts.
Category Scores
Accurate Statements
Cosentyx is a biologic medication used to treat plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Supported for treatment of plaque psoriasis and psoriatic arthritis and ankylosing spondylitis in COSENTYX indications (Section 1) (pediatric 6+ for moderate to severe plaque psoriasis also appears in Section 1/8.4).
Unsupported Statements
The patent for Cosentyx is set to expire in 2028.
No patent-expiration or market-exclusivity timing information in the provided prescribing information excerpts.
In 2028, and possibly before if patent disputes are settled, the market will open up for biosimilar versions of Cosentyx.
No statements about biosimilar market timing, patent disputes, or market entry in the provided label excerpts.
Amgen and Sandoz are developing biosimilars to Cosentyx (secukinumab).
No biosimilar developer/product pipeline information in the provided label excerpts.
Biosimilars to Cosentyx use the same active ingredients as Cosentyx.
No biosimilar comparability/active-ingredient statements in the provided label excerpts.
Biosimilars to Cosentyx have a similar molecular structure to Cosentyx, but may not be identical in all aspects.
No biosimilar molecular-structure comparability statements in the provided label excerpts.
Biosimilars have the same primary and secondary structure as the reference product.
No biosimilar structural comparability statements in the provided label excerpts.
Biosimilars have the same post-translational modifications, purity, and potency as the reference product.
No biosimilar analytical/quality attributes comparability statements in the provided label excerpts.
There can be small differences between biosimilars and the reference product in host cell lines.
No biosimilar manufacturing/source-cell-differences statements in the provided label excerpts.
There can be small differences between biosimilars and the reference product in fermentation procedures.
No biosimilar manufacturing-process differences statements in the provided label excerpts.
There can be small differences between biosimilars and the reference product in final formulation.
No biosimilar formulation differences statements in the provided label excerpts.
Biosimilars are generally expected to be around 15-30% cheaper than the reference product.
No pricing or cost-difference estimates in the provided label excerpts.
Biosimilars may be cheaper than the reference product because they do not have to recoup research and development costs paid by the brand-name company.
No rationale for biosimilar pricing in the provided label excerpts.
Biosimilar prices may vary depending on the manufacturer and the country in which they are sold.
No biosimilar pricing-by-country/manufacturer statements in the provided label excerpts.
Biosimilars must undergo rigorous testing and approval by regulatory agencies such as the FDA before they can enter the market.
No biosimilar regulatory-approval/testing process statements in the provided label excerpts.
Biosimilars require clinical trials to demonstrate similar efficacy compared to the brand-name product.
No biosimilar trial requirements/efficacy-comparability statements in the provided label excerpts.
Biosimilars require clinical trials to demonstrate similar safety compared to the brand-name product.
No biosimilar trial requirements/safety-comparability statements in the provided label excerpts.
Contradictions
Low
AI Statement
Cosentyx is a biologic medication used to treat psoriasis, plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Label Reference
COSENTYX indications (Section 1) as provided do not explicitly mention a general category 'psoriasis' separate from 'plaque psoriasis' in the excerpted text.
Important Omissions
If evaluating label alignment for administration, dosing, contraindications, warnings, interactions, adverse reactions, or monitoring, the provided claims do not address these label sections; therefore, no label-based safety alignment can be assessed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The unsupported claims are primarily about biosimilar economics/market timing and manufacturing comparability rather than COSENTYX dosing, contraindications, warnings, or monitoring. No medication-use directions or contraindication-instructional errors are made.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Most claims are not addressed in the supplied COSENTYX prescribing information excerpts, so they are unsupported by the label. Only indication-related content can be partially matched.
Suggested Improvement
Limit statements to label-supported information in the provided excerpts (e.g., COSENTYX indicated conditions and label safety topics such as infections/TB/IBD, immunizations/live vaccine avoidance, and administration route/formulation instructions). Remove biosimilar market/patent/price/manufacturing/comparability assertions unless the label text provided explicitly supports them.